Stocks · News reference

8-K filing — Vistagen Therapeutics, Inc. (VTGN)

Aug 14, 2026, 12:40 PMSEC EDGAR

Filed: 2026-08-14 AccNo: 0001628280-26-056953 Size: 241 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VTGN

Source: edgar
Observed: Aug 14, 2026, 12:40 PM
Checked: Aug 14, 2026, 12:40 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 14, 2026, 12:50 PMBenzinga Newsdesk
VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 36.17 percent increase over losses of $(0.47) per share
Read original at benzinga
VTGN
BenzingaAug 6, 2026, 12:31 PMBenzinga Newsdesk
Vistagen Says Exploratory Phase 2 Repeat Dose Study Of Fasedienol Missed Statistical Significance On Primary Endpoint (p=0.2); Reports Nominal Significance In Very Severe Social Anxiety Subgroup
Read original at benzinga
VTGN
BenzingaAug 4, 2026, 2:34 PMBenzinga Newsdesk
Vistagen Therapeutics shares are trading higher after SRX Global announced that it has acquired a stake in the company.
Read original at benzinga
VTGN

8-K filing — Vistagen Therapeutics, Inc. (VTGN)

Connected markets

Related headlines

VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate

Vistagen Says Exploratory Phase 2 Repeat Dose Study Of Fasedienol Missed Statistical Significance On Primary Endpoint (p=0.2); Reports Nominal Significance In Very Severe Social Anxiety Subgroup

Vistagen Therapeutics shares are trading higher after SRX Global announced that it has acquired a stake in the company.